Garcinol inhibits the proliferation of endometrial cancer cells by inducing cell cycle arrest

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Endometrial cancer (EC) is a leading cause of cancer deaths in women globally.
• Advanced or recurrent EC has poor long-term survival rates, necessitating novel therapeutic agents.
• Garcinol, a polyisoprenylated benzophenone, shows potential anticancer activity, but its efficacy against EC is unexplored.

Purpose of the Study:

• To investigate the anticancer effects of garcinol on endometrial cancer (EC) cell lines.
• To determine garcinol's impact on EC cell proliferation and cell cycle progression.
• To elucidate the molecular mechanisms underlying garcinol's action in EC.

Main Methods:

• Utilized Ishikawa (ISH) and HEC-1B endometrial cancer cell lines.
• Assessed cell proliferation using real-time assays, cell counting, and colony formation.
• Analyzed cell cycle distribution and DNA synthesis via flow cytometry and EdU incorporation.
• Evaluated protein expression (cyclins, CDKs, p53, p21, JNK pathway) using Western blotting.

Main Results:

• Garcinol significantly inhibited EC cell proliferation in a dose-dependent manner.
• Garcinol induced G1 phase arrest in ISH cells and G2/M phase arrest in HEC-1B cells.
• Garcinol decreased S phase progression and DNA synthesis, upregulated p53 and p21, and downregulated CDK2, CDK4, cyclin D1, and cyclin B1.
• Garcinol increased phosphorylated JNK (c-JUN N-terminal kinase) and p-c-JUN levels.

Conclusions:

• Garcinol demonstrates potent anticancer effects against endometrial cancer cells.
• Garcinol induces cell cycle arrest through modulation of key cell cycle regulatory proteins.
• Garcinol's ability to activate the JNK pathway warrants further investigation.
• Garcinol represents a promising therapeutic candidate for endometrial cancer chemotherapy.